Navigation Links
Trubion Pharmaceuticals, Inc. to Present at the Morgan Stanley Global Healthcare Conference
Date:9/8/2009

SEATTLE, Sept. 8 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced today that executives will present a corporate update at the upcoming Morgan Stanley Global Healthcare Conference in New York City. Peter Thompson, M.D., FACP, president, chief executive officer and chairman of the board of directors, and Michelle Burris, senior vice president and chief financial officer, are scheduled to present on Monday, Sept. 14 at 8 a.m. EDT. The presentation will be available via audio webcast at http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=TRBN&item_id=2400648.

(Logo:http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO)

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The Company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP, therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed SMIP therapeutics such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the Company's Wyeth collaboration. Trubion's product pipeline also includes TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies dev
'/>"/>

SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Trubion Announces Dates for Second Quarter and First Half 2009 Earnings Conference Call
2. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
3. Trubion Announces Acceptance of Three Presentations on Its TRU-016 Product Candidate at the 2009 ASCO Annual Meeting
4. Trubion Announces Dates for First-Quarter 2009 Earnings Conference Call
5. Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting
6. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
7. Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring
8. Trubion Announces Presentations at Upcoming Investor Conferences
9. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
10. Trubion Announces Presentations at Upcoming Investor Conferences
11. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... MESA, Calif. , July 24, 2014  Now ... close to home. Rehealth Regenerative Therapies , located ... athletes and other physically active people a new health ... Regardless of age, countless patients suffer from ... sport activities, such as muscle tears, torn rotator cuff, ...
(Date:7/24/2014)... by group leader Yung-Eun Sung has announced that ... and nitrogen-doped graphenes which can be applied as ... cells. Yung-Eun Sung is both a group leader ... for Basic Science* (IBS) and a professor at ... great significance with regards to the development of ...
(Date:7/24/2014)... 24, 2014 Research and Markets ... Culture Market 2014-2018" report to their offering.  ... culture is the in vitro growth of plant or ... studies, and biopharmaceutical production. Cell culture is a crucial ... instruments and cell culture consumables are necessary for the ...
(Date:7/24/2014)... , July 24, 2014  CorMedix Inc. (NYSE ... and commercializing therapeutic products for the prevention and ... receipt of notice on July 18, 2014 from ... has accepted the CorMedix plan to regain compliance ... a result, the NYSE-MKT is continuing the Company,s ...
Breaking Biology Technology:Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3
... , SOUTHAMPTON, Pa., Jan. 11 Argyce LLC, the trustee ... will divest the remaining drug development program assets of Genaera ... bids to be received no later than February 12, 2010 ... combination. Any person interested in purchasing the assets or learning ...
... PAREXEL International Corporation (Nasdaq: PRXL ) today raised its ... 2010 ended December 31, 2009, and for the full Fiscal ... financial guidance takes into account the projected impact from second ... amount and timing of a previously announced restructuring charge, and ...
... 7 ... , ... -- Genedata, a leading provider of advanced software solutions for drug discovery and life science ... experienced unprecedented industry adoption with 7 out of the 25 leading pharmaceutical companies using Screener ...
Cached Biology Technology:Genaera Liquidating Trust To Sell Remaining Proprietary Assets 2PAREXEL Issues Updated Financial And Operational Information 2PAREXEL Issues Updated Financial And Operational Information 3PAREXEL Issues Updated Financial And Operational Information 4PAREXEL Issues Updated Financial And Operational Information 5Genedata at HCA Announces Banner Year for Genedata Screener at Leading Pharmaceutical Companies 2Genedata at HCA Announces Banner Year for Genedata Screener at Leading Pharmaceutical Companies 3
(Date:7/24/2014)... where electric cars ply silent freeways, solar panels blanket ... the earth, from howling winds and from the blazing ... it is technically and economically feasible to convert California,s ... energy. Published in Energy , the plan shows ... supply in California that could create tens of thousands ...
(Date:7/24/2014)... of researchers has developed a new nanoscale agent for ... for assessing the function and properties of the GI ... and treatment of gut diseases. , Illnesses ... and inflammatory bowel disease all occur in the intestine ... with diseases such as diabetes and Parkinson,s. , ...
(Date:7/24/2014)... this week for an all-day public forum on a ... (EPA) to dredge toxic sediment from an eight-mile stretch ... called the plan, which proposes removing 4.3 million cubic ... riverbed, one of the largest cleanups in the agency,s ... off-site. , "We need to ensure the future well-being ...
Breaking Biology News(10 mins):Stanford study shows how to power California with wind, water and sun 2Stanford study shows how to power California with wind, water and sun 3Stanford study shows how to power California with wind, water and sun 4New imaging agent provides better picture of the gut 2Experts Weigh the Pros and Cons of a $1.7 Billion EPA Cleanup Plan for the Passaic River at an NJIT 2
... genomic DNA around nucleosomes in the cell nucleus makes ... (LMU) in Munich now describes a mechanism that allows ... transcription. In higher organisms the genomic DNA is ... called nucleosomes, each consisting of two pairs of four ...
... new report from the Institute of Medicine says schools should ... minutes of vigorous or moderate intensity activity during each school ... current evidence-based guidelines of at least an hour of vigorous ... which was released today. "Because children are in ...
... world,s largest and fastest growing open-access publishers, announces the ... and Biotechnology . A broad scope journal ... will provide a single open-access platform for diverse ... and discussed. Frontiers in Bioengineering and ...
Cached Biology News:Biochemistry: Unspooling DNA from nucleosomal disks 2Schools should provide students with daily physical activity, IOM recommends 2Frontiers launches new open-access journal in Bioengineering and Biotechnology 2
Agarase cleaves agarose to neoagaro-oligosaccharides, and is used for,quantitative, gentle recovery of DNA from low melting point agarose....
Request Info...
Recombinant Mouse Serpin A1/alpha-1-Antitrypsin, CF Protein Family: Coagulation, Serine Protease Regulators...
X-prolyl aminopeptidase (aminopeptidase P) 1, soluble...
Biology Products: